Retatrutide is an investigational peptide-based drug that activates three key metabolic receptors: GIP, GLP-1, and glucagon receptors.
This triple agonist approach is aimed at providing superior outcomes in weight management and glycemic control by leveraging multiple metabolic pathways. Retatrutide boosts insulin secretion in a glucose-dependent manner, delays gastric emptying, reduces appetite, and promotes energy expenditure through mild glucagon receptor activation. Administered once weekly via subcutaneous injection, the compound has shown remarkable results in early-phase trials, including double-digit percentage reductions in body weight and improvements in insulin sensitivity. While not yet approved for clinical use, retatrutide is considered a promising candidate in the next generation of anti-obesity pharmacotherapy. As with similar agents, contraindications include a personal or family history of medullary thyroid carcinoma or MEN 2.
